Search

By Industry Solutions (2)
By Phase (1)
By Molecule Type (1)
By Therapeutic Area (3)
Covance Events (9)
Geography (3)
Keywords (10)

Filters

Showing results 641 - 656 of 91813 for .

Showing results 641 - 656 of 91813 for .

Intravital Multiphoton Microscopy as a Tool for Drug Development
Discovery Models and Applications to Candidate Selections
Dr. Bill Hanlon speaks about Covance and his experience during the roundtable discussion as part of the House Energy and Commerce Committee's 21st Century Cures initiative.
Dr. Bill Hanlon speaks about Covance and his experience during the roundtable discussion as part of the House Energy and Commerce Committee's 21st Century Cures initiative.
Dr. Bill Hanlon Speaks About Using Existing Data - 21st Century Cures
Dr. Bill Hanlon speaks about using existing data to provide insights to the scientific community during the roundtable discussion as part of the House Energy and Commerce Committee's 21st Century Cures initiative.
Dr. Bill Hanlon Speaks About the Interoperability of Electronic Health Records - 21st Century Cures
Dr. Bill Hanlon speaks about the interoperability of electronic health records during the roundtable discussion as part of the House Energy and Commerce Committee's 21st Century Cures initiative.
Solutions for Your Oncology Trials: Our Experience, Your Insight
Together we can navigate the challenges and develop solutions for your oncology trials.
Growing Value Interactive Tool
An interactive tool: Every stage of your product's development presents an opportunity to grow value.
Advancing Rare Disease Drug Development: Four Key Considerations for Market Access
Our industry is witnessing increasing growth in the rare disease market, thanks to financial and regulatory incentives to develop orphan drugs. This has been good news for both sponsors and patients, but the fact remains that rare disease trials are inherently challenging to run. In addition, completing a complex study and reaching regulatory approval does not necessarily translate to market success.
Clinical Trials and the Growing Importance of Informatics
Demonstrating the efficacy, safety and differential benefit of a new drug relies on collecting and analyzing enormous amounts of data generated in a clinical trial. Yet this process of extracting knowledge from data is often the source of many inefficiencies.
Maximizing the Value of a Product: A Perspective from China
Drug development in China is progressing quickly, due in part to shifting regulations, increased innovation and growing opportunities for global partnerships. However, making Drug Development Market Access Covance Shanghai at night, Chinathe most of market opportunities requires not only a focus on the intended end results but also careful, early phase planning.
Leveraging Big Data to Improve Clinical Trial Performance
As any drug developer knows, clinical trials generate a lot of raw and electronic data from Leveraging Big Data to Improve Clinical Trial Performance Covance Chinamultiple sources. Yet tracking progress and reviewing results from each separate database can be cumbersome in traditional environments. This "rear-view" mirror approach to monitoring doesn't support preventative planning to mitigate future risks and can account for 20-30% of a trial's costs.
Investing in Today's CRA Talent to Ensure a Stronger Tomorrow
The Importance of Clinical Research Associate Training to Support Effective Trials The clinical trial landscape is witnessing an increase in Phase III trials that average more than 3,500 patients. As more of these large trials continue to emerge, many contract research organizations (CROs) and sponsors are struggling to recruit qualified clinical research associates (CRAs) to support the influx of work.